Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Camurus AB ( (SE:CAMX) ) has shared an update.
Camurus AB held its annual general meeting where key resolutions were passed, including the re-election of board members and the election of new members, as well as the approval of fees for board and committee members. The meeting also authorized the board to issue new shares and convertibles, acquire and transfer the company’s own shares, and implement a Performance Share Plan for employees. These resolutions aim to enhance Camurus’ strategic flexibility and align employee incentives with company performance, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.
More about Camurus AB
Camurus is an international biopharmaceutical company focused on developing and commercializing innovative, long-acting medicines to improve the lives of patients with severe and chronic diseases. Utilizing its proprietary FluidCrystal® technology, Camurus develops products for treating dependence, pain, cancer, and endocrine diseases. The company operates in Europe, the US, and Australia, with headquarters in Lund, Sweden, and its shares are listed on Nasdaq Stockholm under the ticker CAMX.
Average Trading Volume: 99,997
Current Market Cap: SEK29.82B
For a thorough assessment of CAMX stock, go to TipRanks’ Stock Analysis page.